Grateful to @BloodJournal, co-authors, and @SWOG for making this #downwithdex piece possible! Dex 40mg weekly in #MMsm induction: 1️⃣ Not practical even for trial-enrolled patients 2️⃣ Does not improve PFS vs ⬇️ dex Twitter 🧵 once I’m back from #IMS24! ashpublications.org/blood/ar…

Today I told a patient his colorectal cancer follow-up is over. No more scans, he's officially cured. Then he picked up his car keys and couldn't feel them properly. That's oxaliplatin. One of the drugs that cured him also damaged the nerves in his hands and feet. For most people it fades. For some it doesn't, years on, still unable to feel a button, a coin, the floor in the dark. We try hard with this: Dose adjustments during treatment, stopping early where we can. Afterwards: specialised physio, occupational therapy, nerve-targeted medication, exercise programmes with real evidence behind them. For some it helps, unfortunately not for everyone. So this patient leaves with both. Cured of the cancer, carrying what curing it cost. Survival gets talked about like a finish line. People cross it and keep walking, with all its consequences. And these consequences get talked about far from enough.

What would Voltaire say about optimizing bridging before CAR-T therapy in multiple myeloma? My best guess below... thanks @TheIACH @Mohty_EBMT for the invitation!

Thanks @Mohty_EBMT for inviting me, and come join us! Everything I've learned about bridging before CAR-T therapy in myeloma. Turns out we had the right idea all along, but partially for the wrong reasons... Today's talk: nuts & bolts of bridging, and where field is headed...

🔴 We are Live! CAR-T: Optimizing Bridging Therapy and Early Response with Rahul Banerjee Join the webinar → us06web.zoom.us/webinar/regi… @RahulBanerjeeMD @Mohty_EBMT

🎙️ In this episode of The HemOnc Pulse, explore how AI is advancing hematologic cancer care through machine learning, genomic data, early detection, clinical decision-making, and patient monitoring with @LouisWilliamsMD and @RahulBanerjeeMD. ➡️ buff.ly/3TnOnG7

Really enjoyed the chance to sit down and have a thoughtful conversation with @RahulBanerjeeMD and @Blood_Cancers. Thank you very much for the invitation. There is so much for us all to learn in this space. @ClevelandClinic @jamecancerdoc

Bortezomib, carfilzomib, lenalidomide, oh my! The treatment landscape for multiple myeloma is changing fast, says @RahulBanerjeeMD. 10 years from now, today's standard therapies may feel like a thing of the past. 🎧 Full conversation with @PGrivasMDPhD: bit.ly/4eebkVd

@RahulBanerjeeMD “meets the Greek” enjoy this new podcast episode @fredhutch @UWMedicine @drtishawang @HutchPresident @mshadman @VenurVyshak @DrOmarMian @spsutkaMD @OncoAlert @VincentRK @thanosdimop @myelomaMD @DimaDanai @cspramesh @neerajaiims @nataliagandur @JasmineKambojMD @FH_IRC

The latest version of the ASCO Multiple Myeloma Living Guideline is out! All published phase 3 data is reviewed every 8 weeks and recommendations are updated in real-time. We are continuing to refine algorithms for relapsed/refractory myeloma as time goes on. ascopubs.org/guidelines/trea…

Hey, myeloma specialists! THANK YOU for doing what you do! I'm grateful to be here, enjoying this glorious fall weather we're having in NY. 🍁 You help make moments like these possible, and I never take that for granted.

Faith bringing it home in the NYC marathon

Hot off the Press: Fortunate to be a part of this effort in collaboration with Geriatric Service at @MSKCancerCenter now published in @BloodCancerJnl🎆🙌🎉 Beyond binary: graded frailty assessment and outcomes after CAR-T cell therapy in relapsed/refractory multiple myeloma rdcu.be/Cg9dNyZSkSRa #MMSM #MedTwitter #MedEd #OncTwitter #CARTcell #OpenAccess @BloodCancerJnl

Hira this is an important math you did; very interesting and thought provoking question; I see that Grade 1 were toci is used is also a higher risk of secondary infections; personally wld love to see what is lowest dose of steroid we can work with.

We use it a lot in AL with cardiac involvement- so much better tolerated than dex

CERVINO has 46 mg of Dex in week one! so Toci proph and Dex 10 mg on SUD and 36 mg with full dose. I do think with higher doses of Dex we see less CRS but i would rather have grade 1 CRS in my older patient than Dex associated delirium.

My kind of humor 💀

I’ve also switched some patients to solu medrol in those who have issues even with lower dose dex.

Super helpful! We need to look at this systematically maybe via one of the databases as very little data on this. And clinical trial protocols need to think of some way of dealing with this too and also some discretion for age/frailty.

For older pts who do not tolerate dex, is anyone reducing the dex empirically during sud and full dosing with BsAb? In many MM trials if you’re > 75, dex is 20 mg/wk, but with BsAb, it can be a high 40-50 mg/wk during step up… i’m seeing more dex related problems than BsAb…

CMS has expanded Medicare coverage for autologous stem cell transplants for patients with multiple myeloma! ASH applauds this decision, which follows collaborative advocacy efforts to improve access to care. Read more: ow.ly/nWke5102qZ0 #Hematology #MMsm